Capricor Therapeutics Inc., of Los Angeles, presented data at the American College of Cardiology 63rd Annual Scientific Session and Expo highlighting positive data from the phase I portion of the company’s ALLSTAR (ALLogeneic heart STem cells to Achieve myocardial Regeneration) phase I/II trial, which met its primary endpoint of safety.